Qin S.Chan S.L.Sukeepaisarnjaroen W.Han G.Choo S.P.Sriuranpong V.Pan H.Yau T.Guo Y.Chen M.Ren Z.Xu J.Yen C.-J.ZHONG-ZHE LINManenti L.Gu Y.Sun Y.Tiedt R.Hao L.Song W.Tanwandee T.2022-06-102022-06-1020191758-8340https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076565560&doi=10.1177%2f1758835919889001&partnerID=40&md5=0dc5aeb27bbe0cae43b92c9a0f0d4c28https://scholars.lib.ntu.edu.tw/handle/123456789/612559[SDGs]SDG3A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinomajournal article10.1177/17588359198890012-s2.0-85076565560